JBTM vs MFP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JBTM is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JBTM and MFP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JBTM and MFP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

JBT Marel Corporation (formerly John Bean Technologies) is a leading technology and equipment supplier to the food and beverage industry, operating in more than 30 countries. It sells processing, preparation, preservation, packaging, and automation systems across poultry, meat, fish, pet food, prepared foods, and beverages, and generates a meaningful and growing share of revenue from recurring aftermarket parts, service, and software. The company reorganized around two reportable segments, Protein Solutions and Prepared Food and Beverage Solutions, after closing its roughly $4.4 billion acquisition of Marel hf. in early 2025 and rebranding as JBT Marel.

Full JBTM guide

Midera Food Processing designs, builds and installs the equipment that industrial food plants use to turn raw inputs into packaged product: continuous thermal cooking and smoking systems (the ALKAR line), grinding, blending and slicing machinery from brands like Cozzini and Thurne, bakery ovens and proofing systems from Baker Perkins, Spooner Vicars and Stewart Systems, and vacuum and tray packaging from RapidPak and Maurer-Atmos. The company markets itself as a total-line supplier, meaning it can sell a bacon, sausage, biscuit or snack producer everything from preparation through thermal processing to final packaging, then keep earning on spare parts, upgrades and service across an installed base it puts at more than ~100,000 units on six continents. It carries more than ~30 brands assembled through more than ~30 acquisitions since 2005, employs roughly ~2,800 people, and is headquartered in Rosemont, Illinois.

Full MFP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JBTM drivers: Marel merger integration and synergies; Recurring aftermarket and software.
• MFP drivers: Aftermarket parts and service on a large installed base; Total-line selling instead of single-machine sales.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The business is cyclical and tied to capital-spending decisions by food processors, so orders can soften in a downturn. For MFP, this is capital equipment, so orders can be deferred quickly when protein producers or bakery customers pull back capex, and Midera has no public record of how its own backlog behaves through a downturn.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JBTM if you believe its drivers more; MFP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JBTM and MFP guides.

JBTM. JBT Marel guided full-year 2026 revenue of roughly $3.99 to $4.065 billion with an adjusted EBITDA margin of about 17.0 to 17.5 percent. The trailing GAAP multiple of ~29 times is inflated by deal amortization, M&A costs and the Q2 impairment; on forward earnings the stock trades near ~11 times and about ~11 times EV to EBITDA, far below where it sat in mid-2026, which reflects the market's doubts about integration timing. The 8 analysts tracked by Yahoo Finance carry a mean target near ~$167, and Barclays started coverage in September at $150.

MFP. Trailing earnings are distorted by separation costs, which is why the trailing P/E looks extreme next to a forward multiple near ~15x on consensus 2027 EPS of about ~$2.58. The raised 2026 outlook calls for ~$160-176 million of standalone adjusted EBITDA, and EV/EBITDA sits near ~16x on trailing figures. The third-quarter report, expected around November 12, 2026 with consensus near ~$0.50 of EPS on ~$220 million of revenue, is the next test of whether margins hold as standalone costs fully land.

Headline figures (approximate, October 2026): JBTM shows revenue (ttm) ~$3.93B; Q2 2026 ~$981M (+5% YoY), adj. ebitda margin (q2 2026) ~17.1%; FY2026 guide 17.0% to 17.5%, net income (ttm) ~$193M, a ~4.9% net margin, adj. eps (q2 2026) ~$1.95 vs ~$2.02 expected; MFP shows revenue (ttm) ~$938 million, up ~13.2% in the latest quarter, 2026 sales outlook ~$935-965 million (raised in August), margins ~35% gross, ~9.7% operating, ~7.1% net, net income (ttm) ~$66.5 million.

JBTM and MFP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JBTM and MFP exposure against your real portfolio. It is not an investment adviser.